Evidence map›Paper›PMID 27170642›Full record

ArticleClinical and vaccine immunology : CVI2016

A Replication-Defective Human Type 5 Adenovirus-Based Trivalent Vaccine Confers Complete Protection against Plague in Mice and Nonhuman Primates.

Jian Sha, Michelle L Kirtley, Curtis Klages, Tatiana E Erova, Maxim Telepnev, Duraisamy Ponnusamy, Eric C Fitts, Wallace B Baze, Satheesh K Sivasubramani, William S Lawrence and 11 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and vaccine immunology : CVI, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. An adenoviral-vectored vaccine protects mice against aerosol challenge with Yersinia pestis.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Article
  3. rLVS ΔHuman vaccines & immunotherapeutics · 2025
    Article
  4. Review
  5. Novel Bivalent mRNA-LNP Vaccine for Highly Effective Protection against Pneumonic Plague.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  6. Article
  7. Review
  8. Article
  9. Zoonoses (Shannon, Ireland) · 2023
    Article
  10. Article
  11. Article
  12. Plague vaccines: new developments in an ongoing search.Applied microbiology and biotechnology · 2021
    Review
  13. Article
  14. SARS-CoV-2: Pathogenic Mechanisms and Host Immune Response.Advances in experimental medicine and biology · 2021
    Article
  15. Vaccines · 2020
    Article
  16. T6SS and ExoA of flesh-eatingProceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 2 institutions in 1 country.

Jian ShaDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, Texas, USA jisha@utmb.edu achopra@utmb.edu.
Michelle L KirtleyDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Curtis KlagesAnimal Resource Center, University of Texas Medical Branch, Galveston, Texas, USA.
Tatiana E ErovaDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Maxim TelepnevDepartment of Pathology, University of Texas Medical Branch, Galveston, Texas, USA.
Duraisamy PonnusamyDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Eric C FittsDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Wallace B BazeDepartment of Veterinary Sciences, M.D. Anderson Cancer Center, Bastrop, Texas, USA.
Satheesh K SivasubramaniGalveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA.
William S LawrenceDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA.
Igor PatrikeevCenter for Biomedical Engineering, University of Texas Medical Branch, Galveston, Texas, USA.
Jennifer E PeelDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA.
Jourdan A AnderssonDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Elena V KozlovaDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Bethany L TinerDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Johnny W PetersonDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, Texas, USA Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA WHO Collaborating Center for Vaccine Development, University of Texas Medical Branch, Galveston, Texas, USA Center for Biodefense and Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, Texas, USA.
David McWilliamsNorwell, Inc., Houston, Texas, USA.
Snehal PatelNorwell, Inc., Houston, Texas, USA.
Eric RotheNorwell, Inc., Houston, Texas, USA.
Vladimir L MotinDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, Texas, USA Department of Pathology, University of Texas Medical Branch, Galveston, Texas, USA Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA WHO Collaborating Center for Vaccine Development, University of Texas Medical Branch, Galveston, Texas, USA Center for Biodefense and Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, Texas, USA.
Ashok K ChopraDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, Texas, USA Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA WHO Collaborating Center for Vaccine Development, University of Texas Medical Branch, Galveston, Texas, USA Center for Biodefense and Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, Texas, USA jisha@utmb.edu achopra@utmb.edu.
The University of Texas Medical Branch at Galveston · USThe University of Texas MD Anderson Cancer Center · US

Funding

Health, Safety and Training ServicesUC7AI070083 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI LEDUC, JAMES W. · 2006 to 2010
$49.5M
Identification of New Antigens for a Plague VaccineR01AI064389 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI CHOPRA, ASHOK K · 2005 to 2015
$3.8M
Biodefense Training ProgramT32AI060549 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI ASHOK K CHOPRA, Janice J Endsley · 2004 to 2026
$3.0M
Evaluation and Production of a Multivalent Adenoviral Plague VaccineR44AI071634 · NIAID · NORWELL, INC. · PI CHOPRA, ASHOK K, ROTHE, ERIC · 2012 to 2014
$2.9M
NIAID NIH HHS R01 AI064389NIAID NIH HHS R44 AI071634NIAID NIH HHS T32 AI060549NIAID NIH HHS UC7 AI070083
6 · The paper itself

Abstract

Currently, no plague vaccine exists in the United States for human use. The capsular antigen (Caf1 or F1) and two type 3 secretion system (T3SS) components, the low-calcium-response V antigen (LcrV) and the needle protein YscF, represent protective antigens of Yersinia pestis We used a replication-defective human type 5 adenovirus (Ad5) vector and constructed recombinant monovalent and trivalent vaccines (rAd5-LcrV and rAd5-YFV) that expressed either the codon-optimized lcrV or the fusion gene designated YFV (consisting of ycsF, caf1, and lcrV). Immunization of mice with the trivalent rAd5-YFV vaccine by either the intramuscular (i.m.) or the intranasal (i.n.) route provided protection superior to that with the monovalent rAd5-LcrV vaccine against bubonic and pneumonic plague when animals were challenged with Y. pestis CO92. Preexisting adenoviral immunity did not diminish the protective response, and the protection was always higher when mice were administered one i.n. dose of the trivalent vaccine (priming) followed by a single i.m. booster dose of the purified YFV antigen. Immunization of cynomolgus macaques with the trivalent rAd5-YFV vaccine by the prime-boost strategy provided 100% protection against a stringent aerosol challenge dose of CO92 to animals that had preexisting adenoviral immunity. The vaccinated and challenged macaques had no signs of disease, and the invading pathogen rapidly cleared with no histopathological lesions. This is the first report showing the efficacy of an adenovirus-vectored trivalent vaccine against pneumonic plague in mouse and nonhuman primate (NHP) models.

Indexed as

Drug CarriersAdenoviruses, HumanAdministration, IntranasalAnimalsAntibodies, BacterialAntigens, BacterialDisease Models, AnimalFemaleImmunization ScheduleInjections, IntramuscularInterferon-gammaMacaca fascicularisMaleMicePlaguePlague VaccineAntibodies, BacterialAntigens, BacterialDrug CarriersInterferon-gammaPlague VaccineVaccines, Synthetic

Identifiers

PMID27170642
PMCPMC4933772
OpenAlexW2376202901

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.